CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
hydroxyureadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000586
NCT00000586Phase 3Completed
CompareCT.gov

Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Oct 28, 1999·Updated Apr 14, 2016

In Brief

A Phase 3 clinical trial evaluating hydroxyurea for Anemia, Sickle Cell and 2 related conditions. Completed.

Detailed Summary

To assess the efficacy and safety of orally administered hydroxyurea in the treatment of painful crises in patients with sickle cell anemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Sickle Cell, Hematologic Diseases, Hemoglobinopathies
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartJan 1, 1992
Primary CompletionJun 1, 1994
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 26.7 years ago

Interventions

hydroxyureadrug